We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prize Reinforcement Contingency Management for Cocaine Dependence: a 24-week Randomized Controlled Trial

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00877435
First Posted: April 7, 2009
Last Update Posted: January 29, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Sylvie Petitjean, University Hospital, Basel, Switzerland
  Purpose
The purpose of this study is to determine whether prize-based contingency management (prizeCM) combined with cognitive behavioral therapy (CBT) is more effective in the treatment of of cocaine-dependent patients compared to CBT only. Patients were randomized to prizeCM + CBT (experimental group) or to CBT (control group) an treated over 24 weeks. It is the first trial of this type in Europe.

Condition Intervention
Cocaine-related Disorders Behavioral: Cognitive behavioral therapy (CBT)

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Prize Reinforcement Contingency Management for Cocaine Dependence: a 24-week Randomized Controlled Trial

Resource links provided by NLM:


Further study details as provided by Sylvie Petitjean, University Hospital, Basel, Switzerland:

Primary Outcome Measures:
  • retention in treatment, cocaine abstinence [ Time Frame: 24 weeks ]
    cocaine abstinence: at least 3 consecutive weeks of cocaine abstinence, the maximum number of weeks of continous abstinence and proportions of cocaine-free urine samples during the entire 24-week and at 6-month follow-up.


Secondary Outcome Measures:
  • patients' satisfaction with the therapy, clinical measures [ Time Frame: 24 weeks ]
    patients' satisfaction with prize-based contingency management and with CBT


Enrollment: 60
Study Start Date: September 2008
Study Completion Date: October 2014
Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Cognitive behavioral therapy (CBT) + prize-based contingency management (prizeCM)
Behavioral: Cognitive behavioral therapy (CBT)
Active Comparator: 2
Cognitive behavioral therapy (CBT)
Behavioral: Cognitive behavioral therapy (CBT)

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • cocaine dependence, aged 18 or older, other dependences

Exclusion Criteria:

  • severe somatic, brain, or psychiatric disease, attention deficit disorders with medication methylphenidate
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00877435


Locations
Switzerland
Universitäre Psychiatrischen Kliniken
Basel, Switzerland, 4025
Fondation Phenix
Geneva, Switzerland, 1221
Sponsors and Collaborators
University Hospital, Basel, Switzerland
Investigators
Principal Investigator: Sylvie A Petitjean, Dr. phil. Psychiatric Hospital of the University of Basel
  More Information

Additional Information:
Responsible Party: Sylvie Petitjean, Dr. phil, University Hospital, Basel, Switzerland
ClinicalTrials.gov Identifier: NCT00877435     History of Changes
Other Study ID Numbers: SNF-105314-120675
First Submitted: April 6, 2009
First Posted: April 7, 2009
Last Update Posted: January 29, 2015
Last Verified: January 2015

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Cocaine
Anesthetics, Local
Anesthetics
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Vasoconstrictor Agents
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents